Business Context and Reporting Period
This Form 8-K Current Report was filed by Exagen Inc. on July 17, 2025. The filing reports corporate governance changes effective as of the same date, specifically the election of a new director and amendments to the non-employee director compensation program.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Composition: The Board of Directors increased in size from seven (7) to eight (8) members.
- Director Appointment: Charles S. McKhann was appointed as a Class III director, with a term expiring at the 2028 annual meeting. He was also appointed to the Compensation Committee and the Nominating Committee.
- Compensation Program: The Board approved an amendment and restatement of the non-employee director compensation program (the "A&R Compensation Program").
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations or future financial performance. The document focuses exclusively on the qualifications of the new director and the terms of his compensation.
Director Compensation Details:
- Initial Grant: 7,500 Restricted Stock Units (RSUs) vesting over four years in equal annual installments.
- Annual Grant: An option to purchase 9,000 shares of Common Stock at fair market value, granted at each annual meeting while serving on the Board. These options vest on the first anniversary of the grant or the next annual meeting, whichever occurs first.
- Cash Compensation: Mr. McKhann will receive cash compensation for service on the Board and its committees in accordance with the A&R Compensation Program.
Investor Verification Checklist
- Verify the full text of the Amended & Restated Non-Employee Director Compensation Program (Exhibit 10.1) to understand specific cash compensation amounts and vesting conditions.
- Review the Press Release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the independence status of Mr. McKhann as disclosed in the filing, noting his prior executive roles at Silk Road Medical, Apollo Endosurgery, and other medical device companies.
- Check subsequent filings for any impact of the increased board size on future corporate governance decisions.